Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multi-Centre Study," published in the March 2025 issue ...

Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...